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Abstract  44 
Introduction: Vascular remodeling in pulmonary arterial hypertension (PAH) results from 45 
smooth muscle cell hypertrophy and proliferation of vascular cells. Loss of bone 46 
morphogenetic protein receptor 2 (BMPR-II) signaling and increased signaling via 47 
transforming growth factor β (TGF-β) and its downstream mediators SMAD2/3 has been 48 
proposed to drive lung vascular remodeling; yet, proteomic analyses indicate a loss of 49 
SMAD3 in PAH.  50 
Objective: We proposed that SMAD3 may be dysregulated in PAH, and that loss of SMAD3 51 
may present a pathophysiological master switch by disinhibiting its interaction partner 52 
myocardin-related transcription factor (MRTF) which drives muscle protein expression. 53 
Methods and Results: SMAD3 was downregulated in lungs of PAH patients, and in 54 
pulmonary arteries of three independent PAH animal models. TGF-β treatment replicated the 55 
loss of SMAD3 in human pulmonary artery smooth muscle (huPASMCs) and endothelial 56 
(huPAECs) cells. SMAD3 silencing increased proliferation and migration in huPASMCs and 57 
huPAECs. Co-immunoprecipitation revealed reduced interaction of MRTF with SMAD3 in 58 
TGF-β treated huPASMCs and pulmonary arteries of PAH animal models. In huPASMC, 59 
loss of SMAD3 or BMPR-II increased smooth muscle actin expression, which was attenuated 60 
by MRTF inhibition. Conversely, SMAD3 overexpression prevented TGF-β induced 61 
activation of a MRTF reporter and reduced actin stress fibers in BMPR2 silenced huPASMC. 62 
MRTF inhibition attenuated PAH and lung vascular remodeling in sugen/hypoxia rats. 63 
Conclusion: Loss of SMAD3 presents a novel pathomechanism in PAH that promotes 64 
vascular cell proliferation and - via MRTF disinhibition - hypertrophy of huPASMC, thereby 65 
reconciling the parallel induction of a synthetic and contractile huPASMC phenotype. 66 
  67 
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Introduction 68 
Pulmonary arterial hypertension (PAH) is a rare but fatal disease, characterized by extensive 69 
remodeling of pulmonary arteries and muscularization of precapillary arterioles1,2. Clinical 70 
and experimental data point towards a central role for TGF-β signaling in PAH, in that a 71 
series of mutations in this pathway have been associated with PAH3–10, and in that TGF-β 72 
expression is increased in pulmonary arteries and lungs of PAH patients and respective 73 
animal models11,12.  74 
By signaling through its canonical pathway, TGF-β, activates receptor-induced SMADs (R-75 
SMADs, namely SMAD2 and SMAD3), which in turn promote gene expression involved in 76 
hypertrophy and fibrosis13. On a simplistic level, the documented elevated plasma levels for 77 
TGF-β in PAH14,15 would therefore lead one to expect that SMADs downstream of TGF-β 78 
may play a crucial role in the pathogenesis of experimental or clinical PAH. 79 
Counterintuitively, however, a significant d crease in pulmonary SMAD3 expression was 80 
detected in PAH animal models as well as IPAH patients11,12 in line with the fact that 81 
prolonged exposure to TGF-β can result in loss of SMAD316. Hence, PAH may actually be 82 
associated with a decrease in the activity of the canonical TGF-β pathway. 83 
While systemic cardiovascular diseases are commonly associated with a switch from a 84 
differentiated vascular smooth muscle cell phenotype with high expression of contractile 85 
proteins and low migration/proliferation abilities to a proliferative dedifferentiated phenotype 86 
with weak contractile protein expression and increased migration, proliferation and resistance 87 
to apoptosis17–20, vascular remodeling in PAH is characterized by both dedifferentiation and 88 
increased smooth muscle cell (SMC) proliferation (hyperplasia), as well as an overall 89 
increase in smooth muscle protein (e.g. α-smooth muscle actin, SMA) expression 90 
characteristic of SMC hypertrophy21. As contractile and proliferative SMC phenotypes are 91 
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commonly considered mutually exclusive, the seeming contradiction of the parallel induction 92 
of both huPASMC hyperplasia and hypertrophy in PAH disease has so far remained 93 
enigmatic. Myocardin related transcription factor (MRTF) is a Rho GTPase responsive, actin-94 
regulated transcriptional co-activator of serum response factor (SRF), a master regulator of 95 
muscle protein expression, including SMA that plays a crucial role in both maintenance of 96 
normal SMC homeostasis22,23 and pathological vascular remodeling24. While the central role 97 
of MRTF in SMC hypertrophy renders it an attractive candidate contributor to vascular 98 
remodeling, MRTF dysregulation in PAH and its underlying mechanism has not yet been 99 
addressed. 100 
MRTF dysregulation may be intrinsically linked to altered TGF-β signalling as suggested 101 
from our previous studies in kidney epithelial cells where we found SMAD3 capable of 102 
binding MRTF, thereby inhibiting MRTF-driven activation of the SMA promoter25–28. Since 103 
SMAD3 may concomitantly exert antiproliferative effects29,30, a general loss of SMAD3 in 104 
PAH may drive both SMA expression via disinhibition of MRTF and huPASMC 105 
proliferation, and thus might explain the parallel existence of a hypertrophic and proliferative 106 
huPASMC phenotype in PAH31–33. To test this notion, we analysed SMAD3 expression 107 
levels in clinical samples and pre-clinical models of PAH, explored the protein-protein 108 
interaction between SMAD3 and MRTF, and their functional roles in huPASMC and 109 
pulmonary artery endothelial cells (huPAEC) relevant to the development and progression of 110 
PAH both in vitro and in vivo. 111 
  112 
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Methods  113 
For full experimental details, including information on proliferation and migration assays, 114 
protein isolation and western blotting, RNA isolation and real-time PCR, cell transfection, 115 
co-immunoprecipitation, animal models of pulmonary hypertension and assessment of their 116 
endpoints please see the online supplement. 117 
Human tissue samples. Human lung tissues were obtained from 7 controls who died 118 
unexpectedly from non-pulmonary causes and 7 PAH patients for which clinical 119 
characteristics are given in Supp. Table 1. Samples were collected under the ethic protocol 120 
#20773 at Laval University and used following current recommendations34. 121 
Cells. HuPASMC and huPAEC were purchased from Lonza, Promocell or isolated from 122 
downsized non-tumorous non-transplanted donor lungs (EK 976/2010, Medical University of 123 
Vienna) and cultured in Smooth Muscle or Endothelial Cell Growth Medium 2, respectively 124 
(Promocell). Murine PASMC were obtained from BMPR2+/R899X mice which carry a mutated 125 
allele of the BMPR2 gene, and corresponding wild type mice as described35. 126 
Transfection. Pre-designed, commercially available siRNA sequences directed against human 127 
SMAD3 and BMPR2 were purchased (Dharmacon Thermo Sientific). For non-specific gene 128 
inhibition of the siRNAs used in this study, a universal negative-control siRNA sequence was 129 
used (Dharmacon Thermo Sientific). For SMAD3 overexpression a GFP-tagged Smad3 from 130 
Clonetech or a Myc-tagged Smad3 expression construct (in pCMV5B) was used. For MRTF 131 
overexpression a FLAG-tagged MRTF construct was used. Cells were transfected with 132 
100nMol/L siRNA or 0.5-2µg plasmid for 8h.  133 
Pulmonary hypertension models. The study was approved by the animal care and use 134 
committee of St. Michael´s, and experiments were performed in accordance with the "Guide 135 
for the Care and Use of Laboratory Animals" (Institute of Laboratory Animal Resources, 7th 136 
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edition 1996). For PAH induction in male Sprague-Dawley rats, both the sugen/hypoxia and 137 
the monocrotaline model were applied. Hemodynamic characterization was performed via 138 
right ventricular systolic pressure (RVSP) measurements and echocardiographic imaging of 139 
right ventricular function, and vascular remodelling and Fulton index were assessed post 140 
mortem. 141 
Statistical analysis. All data are given as means±SEM. Student’s t test (two-tailed) was used 142 
to compare two groups. Where appropriate, a two-way Analysis of Variance (ANOVA) was 143 
applied with Tukey´s post-hoc test. P-values < 0.05 were considered statistically significant.  144 
  145 
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Results  146 
Smad3 is downregulated in clinical and preclinical PAH samples  147 
Total SMAD3 protein levels were significantly decreased in lung lysates from 7 PAH 148 
patients as compared to healthy controls, while SMA expression was concomitantly elevated 149 
(Fig.1A-C). Reduced SMAD3 staining in the intima and media of pulmonary arteries was 150 
also evident by immunohistochemistry in IPAH patients as compared to donor lungs (Supp. 151 
Fig.1). Similar downregulation of SMAD3 was detected in pulmonary arteries of two animal 152 
models of PAH, the monocrotaline (MCT; Fig.1D,E) and the sugen/hypoxia rat model 153 
(Fig.1I,J), whereas TGF-β and smooth muscle actin expression were significantly upregulated 154 
in either model (Fig.1D,F,G,I,K,L). RVSP data for both PAH models are given in Fig.1H,M. 155 
To test whether chronic upregulation of TGF-β in PAH is sufficient to explain this loss in 156 
SMAD3, we probed for the effects of TGF-β on SMAD3 expression in vitro. While short-157 
term exposure to TGF-β for 24h did not alter SMAD3 expression (data not shown), 72h 158 
treatment with 5 ng/mL TGF-β downregulated total SMAD3 levels in huPASMCs at both the 159 
protein and mRNA level (Fig.2A-C). Increasing TGF-β to 10ng/mL caused no further drop in 160 
SMAD3 levels, therefore all subsequent experiments were performed at 5 ng/mL. Decreased 161 
SMAD3 protein levels were similarly detectable in PAECs after 72h exposure to 5 or 162 
10ng/mL TGF-β (Fig.2D,E). Likewise, hypoxia (1% O2) as a trigger of pulmonary 163 
hypertension caused a significant drop in SMAD3 in huPASMCs at the protein (Fig.2F,G) 164 
and mRNA level (Fig.2H) as well as in PAECs (Fig.2I,J). Treatment with interleukin-6 or 165 
platelet-derived growth factor previously implicated in PAH pathogenesis did, however, not 166 
reduce SMAD3 expression in huPASMCs or huPAECs, suggesting that loss of SMAD3 167 
expression is not a universal response to all PAH-related stimuli (Supp. Fig.2). 168 
 169 
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SMAD3 downregulation increases proliferation and migration  170 
To test for functional consequences of SMAD3 loss, we silenced SMAD3 in huPASMC by 171 
siRNA (Fig.3A,B) and assessed fetal calf serum (FCS)-induced proliferation in three 172 
independent assays. SMAD3-silenced huPASMCs exhibited i) higher protein levels for 173 
proliferating cell nuclear antigen (PCNA) (Fig.3A,C), ii) increased staining for nuclear Ki-67 174 
(Fig.3D,E), and iii) higher bromodeoxyuridine (BrdU) levels (Fig.3F) as compared to control 175 
siRNA. A similar increase in FCS-induced proliferation was detectable as higher PCNA 176 
levels in SMAD3-silenced huPAECs relative to internal control (Fig.3G). Graph showing 177 
group data normalized towards siCTL is given in Supp. Figure 6B. Downregulation of 178 
SMAD3 also stimulated huPASMC (Fig. 3H) and huPAEC migration (Fig. 3I) towards an 179 
FCS gradient. Thus, downregulation of SMAD3 is sufficient to replicate two major features 180 
of PAH, enhanced proliferation and migration of huPASMC and huPAEC.  181 
SMAD3 downregulation triggers smooth muscle cell hypertrophy  182 
To test whether SMAD3 loss also triggers huPASMC hypertrophy, we assessed the effect of 183 
TGF-β treatment on the expression of SMA, a differentiation and hypertrophy marker in 184 
SMCs36,37, and on the ratio of total protein to DNA content. TGF-β increased SMA 185 
expression and protein/DNA ratio in a time-dependent manner, which was associated with a 186 
concomitant decrease in SMAD3 levels (Fig.4A-C,E). In line with a direct link between 187 
SMAD3 loss and SMC hypertrophy, SMAD3 protein expression correlated inversely with 188 
both SMA expression (Fig.4D) and protein/DNA ratio (Fig.4F). Consolidating the notion that 189 
loss of SMAD3 directly contributes to increased SMA expression, we next showed that 190 
SMAD3 silencing prior to TGF-β treatment augmented SMA expression in huPASMCs 24h 191 
after TGF-β (Fig.4G,H), whereas 72h after TGF-β no significant difference was observed 192 
between SMAD3 silenced and control siRNA-transfected cells (Fig.4G,I). This observation is 193 
in accord with the fact that by 72h, TGF-β treatment per se caused a drop in SMAD3 194 
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(Fig.4A), thus minimizing the effect of additional SMAD3 silencing (Fig.4G). Taken 195 
together, these experiments substantiate that TGF-β-induced loss of SMAD3 promotes 196 
myogenic (hypertrophic) responses in SMC.  197 
SMAD3-MRTF interaction is decreased by TGF-β treatment 198 
In kidney tubular cells, we showed that SMAD3 interacts with MRTF26 thereby inhibiting its 199 
effect on the SMA promoter38. To test for a similar scenario in PAH where TGF-β-dependent 200 
loss of SMAD3 may accordingly potentiate SMA expression via enhanced MRTF signaling, 201 
we probed for SMAD3-MRTF interaction by co-immunoprecipitation (co-IP). At baseline, 202 
MRTF pulled down substantial amounts of SMAD3, verifying the interaction of these 203 
proteins in resting huPASMCs. TGF-β treatment for 72h reduced the level of MRTF-204 
associated SMAD3 (Fig.5A). This effect is likely attributable to the comparable reduction in 205 
total SMAD3 following TGF-β as evident in the co-IP input (Fig.5B) rather than a reduced 206 
affinity between the two proteins. Interaction between SMAD3 and MRTF was similarly 207 
reduced in pulmonary arteries of MCT (Fig.5C) or sugen-hypoxia (Fig.5D) treated rats, a 208 
finding that is in line with MRTF disinhibition in PAH. 209 
To probe whether loss of SMAD3 may indeed prime cells for enhanced MRTF activity we 210 
treated huPASMC with sphingosine-1-phosphate (S1P), a trigger of MRTF nuclear 211 
translocation and activation39,40. In huPASMC treated with control siRNA, S1P induced SMA 212 
expression in an MRTF-dependent manner, as this effect was blocked by the MRTF inhibitor 213 
CCG1423 (Fig.6A). The latter effect was not attributable to induction of apoptosis by 214 
CCG1423, which could be effectively ruled out for both cell types (Supp.Fig.3&4). SMAD3 215 
silencing amplified S1P-induced SMA expression, which was again sensitive to MRTF 216 
inhibition consistent with an intensified MRTF-dependent signaling following SMAD3 loss 217 
(Fig.6A,B). Next, we expressed the MRTF/SRF-sensitive luciferase reporter 3DA in 218 
huPASMCs and showed that SMAD3 overexpression attenuated reporter activation in 219 
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response to either TGF-β stimulation (Fig.6E) or MRTF overexpression (Fig.6F), 220 
respectively, thus further validating the negative regulation of MRTF-dependent 221 
transcriptional activity by SMAD3.  SMAD3 knock-down also enhanced FCS-induced 222 
proliferation in huPASMCs as assessed by BrdU assay, yet, this effect was not normalized by 223 
CCG1423 (Fig.6C). Similar results were obtained in huPAEC (Fig.6D), indicating that 224 
MRTF disinhibition contributes to hypertrophic yet not hyperplastic responses to loss of 225 
SMAD3 in lung vascular cells.  226 
MRTF inhibition attenuates pulmonary hypertension and vascular remodelling in rats 227 
Based on our findings that i) SMAD3 levels are decreased in clinical and preclinical PAH, 228 
and ii) that loss of SMAD3 drives MRTF-dependent SMA expression, we hypothesized that 229 
pharmacological inhibition of MRTF may alleviate vascular remodeling in experimental 230 
PAH. To address this question, PAH was induced by sugen/hypoxia, and rats were treated 231 
either in a prophylactic approach from day 0 or in a therapeutic approach from day 21 after 232 
SU5416 injection with daily injections of two different doses of CCG1423 or vehicle. As 233 
compared to untreated sugen/hypoxia animals, CCG1423-treated rats showed reduced lung 234 
vascular remodeling (Fig.7A,B) and RVSP (Fig.7C). Echocardiographic parameters of right 235 
ventricular (RV) function were, however, only normalized by prophylactic treatment with 236 
high dose CCG1423, but not with low dose prophylaxis or either therapeutic treatment dose 237 
(Fig.7D,E). This deviation of treatment effects on pulmonary hemodynamics and RV 238 
function may seem surprising; it is, however, in keeping with previous studies41 which 239 
identified impaired RV function as a prominent feature of the sugen/hypoxia model that is 240 
not solely attributable to increased RV afterload, but involves additional direct or indirect 241 
effects on the RV that may be less responsive to MRTF inhibition. 242 
Loss of functional BMPR-II causes SMAD3 loss which in turn drives PASMC 243 
hypertrophy 244 
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Loss of functional BMPR-II signaling, either due to inherited or spontaneous BMPR2 gene 245 
mutations or to acquired loss of BMPR-II42, is a key contributing factor in the pathogenesis 246 
of PAH43,44. To test for a link between impaired BMPR-II signaling and the SMAD3/MRTF-247 
dependent regulation of huPASMC hypertrophy, we made use of a transgenic mouse model 248 
that overexpresses a mutated form of BMPR2 (BMPR2+/R899X) and gradually develops PAH45. 249 
In whole lung lysates of BMPR2+/R899X mice, total SMAD3 levels were markedly reduced as 250 
compared to controls (Fig.8A), indicating that loss of SMAD3 and subsequent MRTF 251 
disinhibition may contribute to lung vascular remodeling in cases of dysfunctional or 252 
deficient BMPR-II. In line with this view, PASMC isolated from BMPR2+/R899X mice had 253 
increased SMA and PCNA expression (Fig.8B,C) as well as decreased total SMAD3 and 254 
BMPR-II protein levels.  255 
To assess if impaired BMPR-II signaling may per se account for loss of SMAD3, we silenced 256 
BMPR2 in huPASMCs which markedly decreased SMAD3 expression (Fig.9A-C). 257 
Consistent with the concept of MRTF disinhibition, SMA expression in response to S1P was 258 
enhanced in BMPR2 silenced cells, and this effect was prevented by CCG1423 (Fig.9A,D). 259 
Silencing of BMPR2 also increased TGF-β expression in huPASMC, providing for a 260 
potential mechanistic link between BMPR-II and TGF-β (Fig.9E-G). Interestingly, MRTF 261 
inhibition also reduced the expression of both SMAD3 and BMPR-II in siCTL-treated cells, a 262 
finding that not only corroborates the tight link of SMAD3 expression to the abundance of 263 
functional BMPR-II, but also suggests that BMPR-II expression may be negatively regulated 264 
by MRTF in a homeostatic feedback loop. To link elevated SMA expression in response to 265 
S1P in BMPR2 silenced cells directly to the loss of SMAD3, we additionally transfected 266 
huPASMC with a SMAD3 expressing plasmid to test whether reconstitution of SMAD3 may 267 
reverse the increase in SMA expression in S1P stimulated, BMPR2 silenced cells. The latter 268 
notion was confirmed, in that BMPR2 silencing increased the formation of actin stress fibers 269 
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and phalloidin staining in S1P-stimulated huPASMC, yet this effect was antagonized and 270 
baseline phalloidin staining reduced in huPASMC overexpressing SMAD3 (Fig.10). 271 
 272 
Discussion 273 
In the present study we identified loss of SMAD3 as characteristic hallmark in different 274 
PAH-related scenarios, and as central pathophysiological mechanism in lung vascular 275 
remodeling. Loss of SMAD3 drives PASMC hypertrophy via disinhibition of MRTF, while 276 
concomitantly stimulating PASMC and PAEC proliferation in an MRTF-independent 277 
manner. Importantly, these findings not only identify a novel shared and potentially 278 
targetable signaling pathway of vascular remodeling in PAH, but also reconcile the 279 
seemingly contradictory parallel stimulation of both contractile and synthetic PASMC 280 
phenotypes in PAH. Induction of this pathway by BMPR-II dysfunction or deficiency 281 
provides for a novel explanation for the propensity of patients with spontaneous or inherited 282 
BMPR2 mutations to develop PAH, and – as we discuss later - resolves the conceptual 283 
dilemma how functional BMPR-II deficiency may promote vascular remodeling given that 284 
BMP/BMPR-II signaling per se induces PASMC differentiation.  285 
In line with previous reports indicating that SMAD3 may be downregulated in experimental 286 
PAH11, we demonstrate here loss of SMAD3 in i) human lung samples of PAH patients, ii) 287 
pulmonary arteries from two preclinical models of PAH, iii) cultured huPASMC stimulated 288 
by TGF-β or hypoxia, iv) a mouse model bearing a heterozygous knock-in allele of a human 289 
BMPR2 mutation, or v) BMPR2-silenced huPASMC. As such, loss of SMAD3 emerges as a 290 
common hallmark in different scale models of PAH disease. The mechanism of SMAD3 291 
downregulation in PAH was not focus of the present work, but is potentially attributable to 292 
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epigenetic regulation via miR-199a-5p, which is upregulated in rat models of PH46 and 293 
negatively regulates SMAD3 expression in huPAEC and huPASMC46. 294 
The role of SMAD3 in cell signaling has classically been viewed primarily in terms of its 295 
function as transcriptional modulator that, upon stimulation of the TGF-β type I receptor, 296 
becomes phosphorylated and, together with SMAD4, translocates to the nucleus where it 297 
regulates the transcription of various TGF-β target genes by binding to the SBE (SMAD-298 
binding element) in their promoter region47. Here, we describe a fundamentally different role 299 
of SMAD3 in the regulation of TGF-β induced gene expression, which is independent of its 300 
phosphorylation and nuclear translocation, but relates to its overall downregulation in 301 
response to TGF-β or in pulmonary hypertension25,48,49. In huPASMC and huPAEC, silencing 302 
of SMAD3 replicated key mechanisms of lung vascular remodeling in PAH, namely cell 303 
proliferation, migration, and – in case of huPASMC – hypertrophy. The parallel induction of 304 
both hyperplastic and hypertrophic responses by SMAD3 loss reconciles these seemingly 305 
opposing effects in a single molecule. 306 
Induction of hypertrophy was attributable to a liberation of the myogenic transcription factor 307 
MRTF from a tonic SMAD3-mediated inhibition. The relevance of SMAD3-MRTF 308 
interaction in vascular homeostasis, and the role of MRTF disinhibition following SMAD3 309 
loss was documented in a series of experiments, in that SMAD3 was shown to co-310 
immunoprecipitate with MRTF in huPASMC at rest, yet MRTF was released from this 311 
interaction upon TGF-β treatment due to loss of SMAD3. Notably, our co-312 
immunoprecipitation experiments focused on MRTF-B; however, we have previously 313 
documented a similar disinhibition by SMAD3 loss for MRTF-A in kidney epithelial cells50, 314 
suggesting a potential synergistic role of both MRTFs in PAH. A similar reduction in 315 
SMAD3-MRTF interaction was detected in pulmonary arteries from sugen/hypoxia or MCT 316 
treated rats. MRTF disinhibition then promotes cell hypertrophy, as demonstrated by the 317 
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finding that SMAD3 silencing amplified SMA expression in response to S1P in an MRTF-318 
inhibitor sensitive manner. Conversely, SMAD3 overexpression attenuated the activation of a 319 
MRTF/SRF reporter in response to TGF-β or MRTF overexpression. The relevance of this 320 
signaling pathway in the context of PAH was confirmed in the sugen/hypoxia model, in that 321 
both prophylactic and therapeutic treatment of rats with an MRTF inhibitor attenuated lung 322 
vascular remodeling and hemodynamic changes. In contrast, MRTF disinhibition did not 323 
contribute to the proliferative effect of SMAD3 loss, since proliferation in response to 324 
SMAD3 silencing was not attenuated by MRTF inhibition. 325 
BMPR2 presents the single most prominent gene implicated in PAH, in that missense, frame-326 
shift, or nonsense mutations in BMPR2 are present in 70% of families with familial PAH, and 327 
in up to 25% of patients with sporadic idiopathic PAH14. Loss of functional BMPR-II 328 
signaling extends, however, beyond BMPR2 mutations, as acquired loss of BMPR-II is a 329 
common trait in nongenetic forms of PAH in humans42 and animal models51. The mechanism 330 
by which functionally relevant mutations or acquired loss of BMPR-II promote PAH has 331 
traditionally been attributed to a shift from a BMPR-II-dependent, SMAD1/5/8 mediated 332 
homeostatic vascular phenotype to a TGF-β-driven, SMAD2/3-mediated vascular 333 
remodeling14. In the present study, however, we show that SMAD3 is largely lost in PASMC 334 
carrying the BMPR2 mutation R899X, or following BMPR2 silencing, while loss of BMPR2 335 
increased TGF-β expression. This finding is reconcilable with an initial predominance of 336 
TGF-β/SMAD2/3 signaling in BMPR2 mutated or silenced cells, which in turn, however, 337 
results in a loss of SMAD3 (Fig. 11). Hence, rather than promoting a long-term increase in 338 
SMAD2/3 signaling, functional loss of BMPR-II may promote PASMC hypertrophy via 339 
disinhibition of MRTF due to loss of SMAD3. Two findings confirm this notion: First, 340 
BMPR2 silencing increased S1P-induced SMA expression in huPASMC in an MRTF-341 
dependent manner. Second, overexpression of SMAD3 prevented the formation of actin 342 
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stress fibers in huPASMC in response to BMPR2 silencing. While these findings establish 343 
loss of SMAD3 and subsequent MRTF disinhibition as important mechanisms driving 344 
PASMC hypertrophy following functional loss of BMPR-II signaling, the role of MRTF in 345 
BMPR-II signaling and lung vascular homeostasis is slightly more complex: Activation of 346 
BMPR-II by BMPs stimulates itself MRTF via the RhoA/ROCK pathway22,23, an effect that 347 
has been proposed to maintain the non-proliferative, differentiated PASMC phenotype in the 348 
healthy pulmonary vasculature22. Conversely, we demonstrate here an important role for 349 
MRTF signaling in PASMC hypertrophy and PAH development. Thus, MRTF’s regulation 350 
differs under healthy (BMPR-dominated) and pathological (TGF-β dominated) conditions. In 351 
the former case MRTF is temporarily activated by BMPR-II and contributes to the 352 
maintenance of the contractile phenotype. In the latter case, MRTF acts on the background of 353 
SMAD3 loss, i.e. in the absence of its tonic inhibitor. This results in prolonged (dysregulated) 354 
MRTF activation, provoking a hypertrophic response that coincides with hyper-proliferation 355 
as an independent consequence of SMAD3 loss. Thus, instead of the normal time-segregation 356 
between proliferative or synthetic responses, PAH is characterized by parallel existence of 357 
both. 358 
The recognition of SMAD3 expression levels as important master switch in the pathogenesis 359 
of PAH not only identifies loss of SMAD3 as new cellular pathomechanism of lung vascular 360 
remodelling, but also constitutes in our view an important conceptual advance in that the 361 
concurrent stimulation of proliferative and hypertrophic signaling pathways reconciles the 362 
seemingly mutually exclusive, parallel induction of a synthetic and contractile huPASMC 363 
phenotype, and recognizes MRTF signaling as a double-edged sword that maintains BMP-364 
regulated vascular homeostasis in the healthy lung, while similarly driving TGF-β induced 365 
lung vascular remodeling in PAH. 366 
 367 
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Figure legends 511 
Figure 1: SMAD3 protein expression is decreased and SMA and TGF-β protein expression 512 
is increased in clinical samples and preclinical models of pulmonary arterial hypertension 513 
(PAH). Representative western blots (A,D,I) and corresponding densitometric quantification 514 
(B,C,E-G, J-L) show SMAD3 and SMA expression in (A-C) total lung lysates of 7 PAH 515 
patients as compared to healthy sex- and age-matched controls (CTL; n=7), and SMAD3, 516 
SMA and TGF-β expression in rat pulmonary arteries after (D-G) 3 weeks of monocrotaline 517 
(MCT) treatment relative to untreated controls (n=8 each), or (I-L) after Sugen/hypoxia 518 
(Su/hyp) relative to untreated controls (n=4 each). RVSP values for MCT and Su/hyp rats 519 
used for protein expression analyses are shown (H,M).*P<0.05 vs. CTL. T-test was applied.  520 
 521 
Figure 2: Stimulation with transforming growth factor-β or hypoxia decreases SMAD3 522 
expression in pulmonary vascular cells. A-E: Representative western blots (A,D), 523 
corresponding densitometric quantification (B,E; n=4-5 independent experiments each) and 524 
mRNA expression levels as determined by real-time PCR (C) show SMAD3 expression in 525 
human pulmonary artery smooth muscle cells (huPASMC; A-C) and human pulmonary 526 
artery endothelial cells (huPAEC; D,E) after 72h stimulation with either 5 or 10 ng/mL 527 
transforming growth factor (TGF)-β, or vehicle control (CTL), respectively. *P<0.05 vs. 528 
CTL. F-J: Representative western blots (F,I), corresponding densitometric quantification 529 
(G,J; n=2-3 independent experiments each) and mRNA expression levels as determined by 530 
real-time PCR (H) show SMAD3 expression in huPASMC (F-H) and huPAEC (I,J) after 72h 531 
stimulation with either 5 ng/mL TGF-β or vehicle control (CTL) in normoxia (21% O2) or 532 
hypoxia (1 %O2), respectively. *P<0.05 vs. CTL; Two-way ANOVA was applied with 533 
Tukey´s post-hoc test.  534 
 535 
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Figure 3: SMAD3 downregulation increases proliferation and migration in pulmonary 536 
vascular cells. A-C: Representative western blots (A) and corresponding densitometric 537 
quantification of SMAD3 (B) and proliferating cell nuclear antigen (PCNA; C) levels (n=4 538 
independent experiments each) show increased PCNA levels upon stimulation with fetal calf 539 
serum (FCS; 5% for 24h) in human pulmonary artery smooth muscle cells (huPASMC) 540 
treated with SMAD3-specific (siSMAD3) relative to control (siCTL) siRNA. *P<0.05 vs. 541 
CTL; #P<0.05 vs. siSMAD3+FCS. D-F: Representative fluorescence microscopic images of 542 
huPASMC immmunostained for Ki-67 (red; marked by arrows) and counterstained with 4',6-543 
diamidino-2-phenylindole (DAPI; blue) (D), corresponding quantification of proliferating 544 
(Ki-67+) cells per image field (E) and quantitative measurement of bromodeoxyuridine 545 
(BrdU) incorporation into huPASMC (F) show increased FCS-induced proliferation in 546 
siSMAD3-treated relative to siCTL-treated huPASMC (n=3-4 independent experiments 547 
each). *P<0.05 vs CTL; #P<0.05 vs. siCTL+FCS. G: Densitometric quantification (n=3-4 548 
independent experiments each) shows increased PCNA levels upon FCS stimulation in 549 
siSMAD3-treated relative to siCTL-treated human pulmonary artery endothelial cells 550 
(huPAEC; n=3-4 independent experiments each). *P<0.05 vs. CTL; #P<0.05 vs. 551 
siCTL+FCS. H,I: Bar graphs show migration of siSMAD3-treated or siCTL-treated 552 
huPASMC (H) or huPAEC (I) in response to FCS stimulation (n>3 independent experiments 553 
each). *P<0.05 vs. CTL; P#<0.05 vs. siSMAD3+FCS, P§<0.05 vs. siCTL+FCS. Two-way 554 
ANOVA was applied with Tukey´s post-hoc test. 555 
 556 
Figure 4: SMAD3 downregulation triggers smooth muscle cell hypertrophy. A-C: 557 
Representative western blots (A) and corresponding densitometric quantification of smooth 558 
muscle actin (SMA; B) and SMAD3 (C) levels (n=4-5 independent experiments each) show 559 
time-dependent increase in SMA expression and parallel loss of SMAD3 in human 560 
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pulmonary artery smooth muscle cells (huPASMC) treated with transforming growth factor 561 
(TGF)-β (5 ng/mL). *P<0.05 vs. CTL. D: Expression levels of SMA and SMAD3 at identical 562 
time points post TGF-β treatment follow a near-linear inverse relationship as determined by 563 
linear regression analysis (dotted line).  E: Group data show protein/DNA ratios in 564 
huPASMC at different time points post TGF-β treatment. F: Protein/DNA ratios and SMAD3 565 
protein expression levels at identical time points post TGF-β treatment follow an inverse 566 
relationship. G-I: Representative western blots (G) and corresponding densitometric 567 
quantification (n=4-5 independent experiments each) show increased SMA expression in 568 
huPASMC treated with SMAD3-specific (siSMAD3) relative to control (siCTL) siRNA at 569 
24h of TGF-β treatment (H; lanes with dotted circumference in G), yet not at 72h (I; lanes 570 
with continuous circumference in G).  *P<0.05 vs. CTL(B, C; E) or siCTL (H);respectively, 571 
n.s., not significant. Two-way ANOVA was applied with Tukey´s post-hoc test. 572 
 573 
Figure 5: SMAD3-MRTF interaction is decreased by transforming growth factor-β 574 
treatment. A,B: Human pulmonary artery smooth muscle cells (huPASMC) were treated for 575 
72h with transforming growth factor (TGF)-β (5 ng/mL) or vehicle (CTL), 576 
immunoprecipitated (IP) with a myocardin-related transcription factor (MRTF) antibody, and 577 
precipitated pellets and supernatant (SUP; showing effective MRTF depletion by IP) were 578 
immunoblotted (IB) for MRTF-B and SMAD3 (A). Densitometric quantification reveals 579 
reduced co-immunoprecipitation (Co-IP) of SMAD3 with MRTF that is quantitatively 580 
comparable to the reduction in total SMAD3 by TGF-β in the input used for the IP (B, n=4 581 
independent experiments). C,D: Pulmonary arteries isolated from monocrotaline- (MCT; C; 582 
full blot see Supp. Figure 6A) or Sugen-hypoxia (Su/hyp) treated rats and corresponding 583 
controls (CTL; n=4-5 independent experiments each) were immunoprecipitated with an 584 
MRTF-antibody, and immunoblotted for MRTF and SMAD3. Densitometric quantification 585 
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demonstrates reduced Co-IP of SMAD3 with MRTF in experimental models of pulmonary 586 
arterial hypertension. *P<0.05 vs. CTL.T-test was applied. 587 
 588 
Figure 6: Loss of SMAD3 primes for enhanced MRTF activity. A,B: Representative western 589 
blots of smooth muscle actin (SMA) and SMAD3 (A) and corresponding densitometric 590 
quantification of SMA (B) levels (n=5 independent experiments each) show increased 591 
expression of SMA following myocardin-related transcription factor (MRTF) activation by 592 
sphingosine-1-phosphate (S1P; 1 µMol/L) in human pulmonary artery smooth muscle cells 593 
(huPASMC) treated with SMAD3-specific (siSMAD3) relative to control (siCTL) siRNA 594 
that is sensitive to MRTF inhibition by CCG1423 (5µMol/L). *P<0.05 vs. siCTL+S1P; 595 
#P<0.05 vs. siSMAD3+S1P. C-D: Quantitative measurement of bromodeoxyuridine (BrdU) 596 
incorporation into huPASMC (C) or huPAEC (D) shows increased proliferation in response 597 
to fetal calf serum (FCS; 5%) as compared to vehicle in both siCTL- and siSMAD3-treated 598 
huPASMC or huPAEC, and increased BrdU incorporation in siSMAD3 as compared to 599 
siCTL-treated, FCS-stimulated huPASMC or huPAECs that is, however, not reversed by the 600 
MRTF inhibitor CCG1423 (n>3 independent experiments each). *P<0.05 vs. siCTL; 601 
#P<0.05 vs. siCTL+ CCG1423; §P<0.05 vs. siSMAD3; $P<0.05 vs. siSMAD3+CCG1423. 602 
Two-way ANOVA was applied with Tukey´s post-hoc test. E-F: Group data show luciferase 603 
reporter activity of the MRTF/SRF sensitive promoter 3DA in TGF-β treated huPASMCs 604 
overexpressing an empty-GFP or SMAD3-GFP plasmid (E; n=3 each) or huPASMCs co-605 
expressing MRTF-FLAG with an empty-GFP or SMAD3-GFP overexpressing plasmid (F, 606 
n=3). *P<0.05 vs. CTL. T-test was applied. 607 
 608 
 609 
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Figure 7: MRTF inhibition attenuates pulmonary hypertension and vascular remodelling in 610 
rats. Representative hematoxylin & eosin stainings show lung vascular remodelling (A), and 611 
bar graphs show vascular wall thickness relative to vessel diameter in lung microvessels of 612 
<50 µm, 50-100 µm, and >100 µm diameter (B), right ventricular systolic pressure (RVSP; 613 
C), and echocardiographic analysis of  tricuspid anular plane systolic excursion (TAPSE; D) 614 
and pulmonary artery acceleration time (PAAT; E). Rats were either kept under normoxic 615 
conditions, or underwent treatment with Sugen/hypoxia (Su/hyp) for induction of pulmonary 616 
arterial hypertension, and were treated with either vehicle (DMSO), the myocardin-related 617 
transcription factor (MRTF) inhibitor CCG1423 (0.15mg/kg), or a five-fold higher dose of 618 
CCG1423 (0.75mg/kg; 5xCCG1423) from day 0  or as therapeutic approach from day 21 619 
after SU5416 injection (n=5-10 rats per group). *P<0.05 vs normoxic vehicle control, 620 
#P<0.05 vs Su/hyp+vehicle.  621 
 622 
Figure 8: Loss of functional bone morphogenetic protein receptor 2 causes downregulation 623 
of SMAD3. A: Representative western blots show SMAD3 protein expression in total lung 624 
lysates of BMPR2+/R899X and corresponding wild type (WT) mice (replicated in n=3 625 
independent experiments each). B,C: Representative western blots and corresponding 626 
densitometric quantification of bone morphogenetic protein receptor 2 (BMPR-II), smooth 627 
muscle actin (SMA), proliferating cell nuclear antigen (PCNA), and SMAD3 show loss of 628 
BMPR-II and SMAD3, and increased proliferation and SMA expression in pulmonary artery 629 
smooth muscle cells isolated from lungs of BMPR2+/R899X mice as compared to those from 630 
WT mice (n=4 independent experiments each). *P<0.05 vs. WT. T-test was applied. 631 
 632 
Figure 9: Loss of functional bone morphogenetic protein receptor 2 drives smooth muscle 633 
hypertrophy in a myocardin-related transcription factor and SMAD3 dependent manner. A-634 
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C: Representative western blots (A) and corresponding densitometric quantification show (B) 635 
successful BMPR2 silencing, (C) loss of SMAD3 in human pulmonary artery smooth muscle 636 
cells (huPASMC) treated with BMPR2-specific (siBMPR2) relative to control (siCTL) 637 
siRNA, and (D) increased expression of smooth muscle actin (SMA) following myocardin-638 
related transcription factor (MRTF) activation by sphingosine-1-phosphate (S1P; 1 µMol/L) 639 
in siBMPR2-treated as compared to siCTL-treated huPASMC that is sensitive to MRTF 640 
inhibition by CCG1423 (5 µMol/L) (n=9 independent experiments each). *P<0.05 vs siCTL; 641 
#P<0.05 vs siBMPR2+S1P. T-Test was applied. E-G: Representative western blots (E) and 642 
corresponding densitometric quantification show increased TGF-β (F) expression after 643 
BMPR2 silencing (G).  644 
 645 
Figure 10: Representative immunofluorescence images show siCTL- or siBMPR2-treated 646 
huPASMC stimulated by S1P (1 µMol/L) or vehicle and transfected with a SMAD3-Myc 647 
plasmid stained for F-actin by phalloidin alone (left; green) or (right) in combination with 648 
anti-SMAD3 staining for SMAD3 (red) and diamidino-2-phenylindole (DAPI; blue). 649 
SMAD3-overexpressing cells are outlined by dotted lines. Representative images and 650 
quantitative analysis of mean phalloidin fluorescence intensity in SMAD3-overexpressing as 651 
compared to adjacent non-transfected cells show reduced formation of actin stress fibers in 652 
SMAD3-overexpressing cells at rest, after stimulation with S1P or BMPR2 silencing, or a 653 
combination of both (replicated in n=3 independent experiments each). *P<0.05 vs siCTL; 654 
#P<0.05 vs siCTLplasmid group; One-way ANOVA was applied with Tukey´s post-hoc test. 655 
 656 
Figure 11: Schematic of proposed signalling pathway. 657 
Short term and long term (chronic) effects of TGF-β stimulation on pulmonary artery smooth 658 
muscle cells. Initially, TGF-β signaling via the classic SMAD2/3 signaling axis 659 
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predominates, resulting in expression of SMAD3-dependent target genes but antagonizing 660 
TGF-β induced MRTF activation by SMAD3-MRTF interaction. Chronic TGF-β stimulation, 661 
however, leads to downregulation of SMAD3 (red dotted line) and therefore, reduced 662 
expression of SMAD3-dependent target genes. Functional loss of BMPR-II receptor 663 
signaling due to BMPR2 mutations or receptor downregulation, respectively, replicates this 664 
effect, presumably in part by increasing TGF-β expression. Loss of SMAD3 then stimulates 665 
cell proliferation and migration in an MRTF-independent manner and concomitantly 666 
disinhibits MRTF (indicated by red cross) allowing MRTF to translocate into the nucleus and 667 
together with serum response factor (SRF) drive the SMA promoter, thus promoting both 668 
hypertrophy and hyperplasia in parallel.  669 
 670 
 671 
  672 
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Online Supplement  
Methods 
Cells. Human pulmonary arterial smooth muscle cells (huPASMC) and human pulmonary 
arterial endothelial cells (huPAEC) purchased from Promocell (C-12521, Heidelberg, 
Germany) and Lonza (CC-2530, Basel, Switzerland), respectively, were cultured either in 
Smooth Muscle (C-22062) or Endothelial Cell Growth Medium 2 (C-22211) both purchased 
from Promocel and used from passage 4-8. Murine PASMC were obtained from 
BMPR2+/R899X mice which carry a mutated allele of the BMPR2 gene, and corresponding wild 
type mice as previously described 1, and cultured in Smooth Muscle Growth Medium 2 
(Promocell). 
 
Protein isolation and western blotting. For protein extraction, human (donor and PAH) as 
well as rat lung samples (normoxic, SU5416/hypoxia as well as MCT treated rats) were 
ground in liquid nitrogen. HuPASMC or huPAEC were lysed in RIPA buffer with protease 
inhibitor complex and phosphatase inhibitors (Roche, Basel, Switzerland). After incubation 
on ice for 30 minutes, samples were centrifuged (12,000g, 10 min, 4°C), and the protein 
concentration in the supernatant was determined by spectrophotometry (BCA assay, Pierce, 
Rockford, IL, USA). Final concentrations of 10 µg of protein were run on a 10% sodium 
dodecyl sulfate (SDS) polyacrylamide gel, followed by electrotransfer to a 0.2-µm pore 
nitrocellulose membrane (Bio-Rad, Bio-Rad Laboratories, Mississauga, Ontario, Canada). 
After blocking with 5% non-fat dry milk in TBS-T buffer (Tris-buffered saline with 0.1% 
Tween20), the following antibodies were applied over night at 4°C: SMAD3 (1:1000; 
#9523S; Cell Signaling Technology, Danvers, MA, USA), MRTF-B (1:2000; sc61074; Santa 
Cruz Biotechnology, Dallas, Texas, USA), SMA (1:10000; A2547; Sigma Aldrich), PCNA 
(1:2000; #2586S; Cell Signaling Technology, Danvers, MA, USA), BMPR-II (1:1000; 
612292; BD Biosciences, Mississauga, ON, Canada); TGF-β (1:2000; ab179695; Abcam; 
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Cambridge, United Kingdom ); PARP (1:1000; #9542; Cell Signaling Technology, Danvers, 
MA, USA); GAPDH (1:5000; sc25778; Santa Cruz Biotechnology, Dallas, Texas, USA), 
tubulin (1:10000; #2125S; Cell Signaling Technology, Danvers, MA, USA). Secondary 
antibodies were purchased from Jackson ImmunoResearch and applied at a 1:5000 dilution. 
Final detection of proteins was performed using the Amersham ECL Prime Western Blotting 
Detection System (GE Healthcare, Wien, Austria).  
Transfection. Pre-designed, commercially available siRNA sequences directed against 
human SMAD3 and BMPR2 were purchased (Dharmacon Thermo Sientific). For non-
specific gene inhibition of the siRNAs used in this study, a universal negative-control siRNA 
sequence was used (Dharmacon Thermo Sientific). For SMAD3 overexpression a GFP-
tagged Smad3 from cClonetech or a Myc-tagged Smad3 expression constructs (in pCMV5B) 
was used which was a kind gift from L. Attisano (University of Toronto). ) , for MRTF 
overexpression a FLAG-tagged MRTF construct kindly provided by E.N. Olsen (University 
of Texas, Southwestern Medical Center, Dallas, TX) . Cells were transfected with 100nMol/L 
siRNA or 0.5-2µg plasmid for 8h using Effectene, Transfection Reagent (Qiagen, Toronto, 
Ontario, Canada) .  
 
Proliferation assays. For SMAD3 silencing, huPASMCs or huPAECs were treated for 8 h 
with SMAD3-specific (siSMAD3) or scrambled (siCTL) small interference RNA (100nMol/L 
L-020067-00-0005 or D-001810-10-05, respectively; Dharmacon Thermo Scientific)). 
Tenthousand cells per well were seeded on 96 well plates and kept overnight in starvation 
medium (0% FCS). The following day cells were stimulated with basal media with or without 
5% FCS and or 5 µMol/L CCG1423 (10010350; Cayman Chemical, Ann Arbor, Michigan; 
USA). Proliferation of huPASMCs and huPAECs was determined by immunoblotting for 
proliferating cell nuclear antigen (PCNA #2586, Cell Signaling Technology, Danvers, MA, 
USA), by incorporation of bromodeoxyuridine (BrdU assay) according to manufacturer 
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instructions (#6813; Cell Signaling Technology, Danvers, MA, USA), or by 
immunocytochemical staining for Ki-67, respectively. 
 
Migration assay. huPASMCs and huPAECs were treated with siSMAD3 or siCTL as 
described above. The next day, 20,000 cells per 24-transwell (CA62406-198; VWR, 
Mississauga, Ontario, Canada) were seeded and allowed to migrate towards basal medium 
with or without 5% FCS for 6h. Cells were fixed with ice-cold methanol and stained with 
haematoxylin. Residual non-migrated cells in the compartment of the transwell were removed 
and migrated cells on the lower filter insert were counted manually.  
 
RNA isolation and real-time PCR. Total cellular RNA was isolated from huPASMCs and 
huPAECs by use of the RNeasy Mini Kit from Qiagen (Toronto, Ontario, Canada). A 
Nanodrop 2000c spectrophotometer (PeQlab) was used to quantify the concentration and the 
purity of the isolated total RNA. Total RNA was reverse transcribed to cDNA using an 
iScript™ cDNA Synthesis Kit (Bio-Rad, Mississauga, Ontario) and amplified using a 
Lightcycler 480 (Roche, Basel, Switzerland). The PCR reactions were performed with 
QuantiFast SYBR PCR kit (Qiagen, Toronto, Ontario, Canada). Gene expressions were 
calculated using the ∆Ct method with GAPDH serving as control.  
 
Co-immunoprecipitation. Cell lysates of TGF-β (5 ng/mL for 72 h) or vehicle treated 
huPASMCs, or pulmonary arteries isolated from MCT, Sugen-hypoxia, or control rats were 
incubated with an antibody directed against MRTF-B (1:100; Santa Cruz Biotechnology, 
Dallas, Texas, USA) over night at 4°C. To collect the formed complex composed of anti-
MRTF-B antibody bound to MRTF-B and possible binding partners (SMAD3), protein G (or 
A) sepharose was added the next day for 1h at 4°C. After centrifugation (3-5 min at 2,000 
rpm at 4°C) and 5x washing with cell lysis buffer, the supernatant of the sample was carefully 
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removed and 2x concentrated SDS-PAGE sample loading buffer with denaturising β-
mercaptoethanol was added to the pellet. The samples were boiled at 95°C for 10 min and 
western blots for   SMAD3 (1:1000; Cell Signaling Technology, Danvers, MA, USA) and 
MRTF-B (1:2000; Santa Cruz Biotechnology, Dallas, Texas, USA) protein levels were 
performed on the immunoprecipitated pellet, as well as the supernatant and the original input 
(cell lysate) as corresponding controls. 
 
Immunocytochemistry. Cells were fixed with 4% methanol-free paraformaldehyde and 
treated for 10 min with 100 mMol/L glycerol followed by 15 min of 0.1% TritonX100 
(Sigma). After 1h 5% treatment with bovine serum albumin (BSA) cells were stained with 
anti-SMAD3 (1:100; Cell Signaling Technology, Danvers, MA, USA) for 1h at room 
temperature. Alexa Fluor555 donkey-anti-rabbit (1:200; Thermo Fisher Scientific) was 
applied as secondary antibody. For actin staining Alexa Fluor Phalloidin488 (1:100; Thermo 
Fisher Scientific) was applied for 1h at room temperature. Mounting medium with DAPI was 
used from Vectorshield, Burlingame, Canada.. Pictures were taken with an Nikon Upright 
E800 microscope.  
 
Immunohistochemistry. Serial cut human lung slides from donor or IPAH patients were 
deparaffinized and stained for SMAD3 (1:100, #9523S; Cell Signaling Technology, Danvers, 
MA, USA) or SMA (1:300, A2547; Sigma Aldrich) overnight in 4°C; secondary antibody 
staining was performed with the Vektor ImmPRESS reagent kit (Vector Laboratories Ltd, 
Peterborough, UK). Hematoxylin was applied for counterstaining.  
 
Flow cytometry: For caspase-3 analysis, cells were treated either with 1µMol/L or 5µMol/L 
CCG1423 for 24h or 48h. Staurosporine (0.1µMol/L) served as positive control. Cells and 
supernatant were collected, centrifuged and washed with PBS. For caspase 3 staining the 
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CellEvent™ Caspase-3/7 Green Flow Cytometry Assay Kit was employed according to the 
manufacturer´s instructions (C10427; Life Technologies, Carlsbad, CA), and caspase-3 
positive events were detected and analysed on a CytoFLEX using CytExpert software 
(Beckman Coulter Life Sciences, Indianapolis, IN). For Ki-67 analysis, cells were fixed in 
1% parafomraldehyde (PFA) for 15min on ice. After 15min treatment with 0.3% saponin and 
subsequent PBS washing steps, cells were stained for 20min with a Ki-67 phycoerythrin-
labeled antibody (Ki-67 PE set, Becton Dickinson, Vienna, Austria), and analyzed on a LSRII 
cytometer (Becton Dickinson, Franklin Lakes, NJ, USA, State).  
 
Luciferase Reporter Assays: Assays were carried out as described previously (2). Briefly, 70 
– 80% confluent PASMCs were incubated in 0% serum for 2 hr and then co-transfected using 
0.6 µL/mL of Human Artery Smooth Muscle Cell Avalanche (EZ Biosystems, LLC) 
according to manufacturer’s instructions. Cells were co-transfected with the MRTF/SRF 
sensitive promoter plasmid pGL3-3DA-Luc (0.25 µg/mL) which contains the firefly 
luciferase gene under the control of a CArG box triplet, the control plasmid pRL-TK (0.05 
µg/mL), and one of the following four constructs: empty GFP (0.5 – 2 µg, Clonetech, 
Mountain View, CA ,USA), GFP-Smad3 (0.5 – 2 µg, Clonetech), pcDNA (0.1 µg, Invitrogen, 
Burlington, ON, Canada), FLAG-MRTFB (0.1 µg, kindly provided by E.N. Olsen, Univ. of 
Texas Southwestern Medical Center, Dallas, TX). Cells were treated 24h later as described 
for individual experiments and lysed on ice with 1x Passive Lysis Buffer (Promega, Madison, 
WI, USA). The luciferase assay was conducted using the Dual Luciferase Kit (Promega) as 
per manufacturer’s instructions.  
 
Pulmonary hypertension models. The study was approved by the animal care and use 
committee of St. Michael´s (ACC #554), and all experiments were performed in accordance 
with the "Guide for the Care and Use of Laboratory Animals" (Institute of Laboratory Animal 
Resources, 7th edition 1996).  
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Sugen-hypoxia model: Male Sprague-Dawley (Charles River Laboratories, St. Constant, QC ) 
rats with a starting body weight (bw) of 200g received a single subcutaneous injection of the 
VEGF receptor antagonist SU5416 (20 mg/kg bw dissolved in 0.5% carboxymethylcellulose 
sodium + 0.9% sodium chloride + 0.4% Tween80 + 0.9% benzyl alcohol in distilled water) 
and were subsequently exposed to 10% O2 (hypoxia) for 3 weeks, followed by 2 weeks of 
normoxia (21% O2) as previously described3. In subgroups of animals, the pharmacological 
MRTF inhibitor CCG1423 (0.15mg/kg or 0.75mg/kg [5xCCG1423] in DMSO, Cayman 
Chemicals, Ann Arbor, Michigan, USA) or respective vehicle was delivered daily via 
intraperitoneal injections either from day 0 (prophylactic approach) or from day 21 
(therapeutic approach) after SU5416 injection. 
Monocrotaline model: Male Sprague-Dawley rats (Charles River Laboratories, St. Constant, 
QC) with a starting bw of 200 g were treated with either a single intraperitoneal injection of 
monocrotaline (MCT; 60 mg/kg, Sigma, Deishofen, Germany in distilled water, pH: 7.5) or 
vehicle alone. After 21 days the animals underwent hemodynamic characterization (vide 
infra) and were sacrificed for organ harvesting.  
 
Hemodynamic characterization. Rats were anesthetized by isoflurane inhalation (5%). 
Right ventricular systolic pressure (RVSP) measurements were performed as previously 
described 4 using a closed chest technique. Briefly, a 1.4 mm pressure catheter (Millar 
Instruments, Houston, TX, USA) was inserted into the jugular vein and directed to the right 
ventricle. Pressure recordings were made over a two minute period each and analyzed with 
Powerlab Pro software (AD Instruments Spechbach, Germany).  
Echocardiographic imaging of right ventricular function was performed in anesthetized rats 
using a 12-MHz probe  (Hewlett Packard Sonos 5500, Philips, Ultrasound, Bothell), and 
tricuspid anular plane systolic excursion (TAPSE) and pulmonary artery flow acceleration 
time (PA time) were quantified as surrogates for pulmonary hypertension. 
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Vascular remodelling. Hematoxylin and eosin staining was performed on paraffin fixed lung 
tissue slides. For quantification of medial wall thickness, external and internal (lumen) area as 
well as vessel diameter was determined for all pulmonary arteries within the field of 
observation, and the difference between external and internal vessel area relative to the 
external area was quantified. Vessels were categorized according to external diameter in <50 
µm, 50-100 µm, and >100 µm pulmonary arteries. 
 
Fulton Index. After exsanguination, lungs and hearts were isolated. The right ventricle (RV) 
was dissected from the left ventricle and septum (LV+S) and the samples were weighed 
separately to obtain the right-to-left ventricle plus septum weight ratio [RV/(LV+S); Fulton 
index] as a measure of right ventricular hypertrophy. 
 
Statistical analysis. Statistical analyses were performed by use of GraphPad Prism software 
(GraphPad Prism 6.0; GraphPad Software Inc., La Jolla, CA). All data are presented as means 
± SEMs. Student’s t-test (two-tailed) was used to compare two groups. For >2 groups, two-
way Analysis of Variance (ANOVA) was applied and Turkey was used as a post-hoc test. 
Linear regression analysis was performed by GraphPad Prism software. P-values < 0.05 were 
considered as statistically significant. 
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Supplementary Table 1: Clinical data of patient cohort given in mean+/- SEM 
  Control PAH 
body mass index (kg/m2) 26±2 22.8±4.7 
WHO / NYHA NA III and IV 
TVC (POD/RAP/PVC) (mmHg) NA 13.5±5.4 
systolic pulmonary arterial 
pressure (PAP) (mmHg) NA 81±14.8 
diastolic PAP (mmHg) NA 33±4.2 
mean PAP (mmHg) NA 51±8.8 
systolic blood pressure (mmHg) NA 113±10.1 
diastolic blood pressure (mmHg) NA 69±6.6 
mean blood pressure (mmHg) NA 88±9.6 
cardiac output (L/min)  NA 4±1.1 
cardiac index  (L/min/m2) NA 2±0.5 
pulmonary capillary wedge 
pressure (mmHg) 
NA 10±3.1 
SvO2 mixed venous oxygen 
saturation (%) 
NA 56±10.7 
heart rate (bpm) NA 82±9.2 
pulmonary vascular resistance 
(PVR) (dyne·s·cm-5) NA 808±66.3 
arterial oxygen saturation  
(SaO2) (% at rest) 
NA 91±2.8 
6 min walk distance (m) NA 281±101 
arterial oxygen saturation  
(SaO2) (% after 6min) 
NA 81±7.7 
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Supplementary figure legends: 
Suppl. Fig. 1: Serial sections of human lungs from healthy donors or IPAH patients were 
immunohistochemically stained (in red) for SMAD3 (left) or smooth muscle actin (SMA; 
right). Nuclei were counterstained blue with Hematoxylin. Lower panels show enlarged areas 
as indicated in top panels.  
 
Suppl. Fig. 2: HuPASMC (A, B) and huPAEC (C, D) were treated either with platelet-
derived growth factor (PDGF; 10ng/mL and 100ng/mL) or interleukin-6 (IL-6; 10ng/mL or 
100ng/mL) and probed for SMAD3 protein expression. Representative western blots are 
shown in A,C and quantitative data in B,D (n=7-8 each; *P<0.05 vs. control, CTL). 
 
Suppl. Fig. 3: Effect of 24h and 48h treatment with either 1µMol/L or 5µMol/L CCG1423 on 
activated caspase 3 expression as measured by flow cytometry in either huPASMC (A) or 
huPAEC (B). Staurosporine (0.1 µMol/L) served as positive control. Representative 
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histograms and quantitative data for the percentage of activated caspase 3 positive cells are 
shown (n=3 each; *P<0.05 vs. corresponding time control, CTL). 
 
Suppl. Fig. 4: Effect of 24h and 48h treatment with either 1µMol/L or 5µMol/L CCG1423 on 
Poly (ADP-ribose) polymerase (PARP) cleavage in either huPASMC (A) or huPAEC (B). 
Staurosporine (0.1 µMol/L) served as positive control. Representative western blots for total 
PARP, cleaved PARP and GAPDH as loading control are shown as well as quantitative data 
for cleaved PARP normalized either to total PARP or GAPDH, respectively (n=4 each; 
*P<0.05 vs. corresponding time control, CTL).  
 
Suppl. Fig. 5: Ki-67 expression is decreased in SMAD3 overexpressing huPASMCs 
following 72h stimulation with 5ng/ml TGF-β and 24h with 5% FCS. Ki-67 positivity was 
determined by flow cytometry in GFP positive cells overexpressing either GFP-linked control 
(CTL) plasmid or GFP-linked SMAD3 plasmid, treated with or without TGF-β and/or FCS 
(n=3 each; *P<0.05 vs CTL-CTLplasmid. 
 
Suppl. Fig. 6: (A) Uncropped western blot shown in Figure 5C. (B) Alternative to Figure 3C 
PCNA western blot quantification summary. Data was normalized to siCTL  
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